

NEXALIS TO PRESENT AT NWR VIRTUAL HEALTHCARE CONFERENCE

Melbourne, Australia – Nexalis Therapeutics Ltd ('**NX1**' or the '**Company**') is pleased to announce that it will present at the NWR Virtual Healthcare Conference.

CEO Darryl Davies will present at **8:30am AEDT on Thursday 26 March 2026**.

Shareholders, investors and interested parties are encouraged to register to attend the presentation at the following link: https://us02web.zoom.us/webinar/register/WN_iytQ5f-WT_i2fscSIEmW-Q

A recording will be available at the above link shortly after the conclusion of the live session, and the replay will also be available via the Company's website and social media channels.

Questions can be submitted on the day or sent in advance to matt@nwrcommunications.com.au

For more information please visit: <https://nwrcommunications.com/healthconf>

Authorised for release by the Board of Directors.

For further information:

www.nexalistherapeutics.com

James Barrie, Company Secretary

T: +61 3 9070 1221

E: investors@nexalistherapeutics.com

Investor relations

Matthew Wright

NWR Communications

M: 0451 896 420

E: matt@nwrcommunications.com.au

ABOUT NEXALIS THERAPEUTICS LTD (ASX: NX1)

Nexalis Therapeutics Ltd is an Australian Clinical Stage Drug Development Company that is developing rapid onset, inhaled therapies to address unmet medical needs in pain management and mental health sectors. The Company has secured a funding partner with a facility of up to \$52.3m to accelerate the development of IRX-211 to treat Breakthrough Cancer Pain ('**BTcP**'), IRX-616a to treat Panic Disorder ('**PD**') and SRX-25 for the treatment of Treatment-Resistant Depression ('**TRD**').

The overarching goal is to pursue U.S. FDA approval and registration using rapid and cost-effective regulatory pathways, such as 505(b)(2).

There is a significant economic opportunity for NX1 and the Company's shareholders, the clinical indications under investigation have been carefully selected in consultation with regulatory authorities. Bringing new approved medications to market will address critical gaps whereby there's currently mismatched treatment options that can carry dependency concerns.

CONTACT US

NEXALIS THERAPEUTICS

T: +61 3 9070 1221 | E: investors@nexalistherapeutics.com | W: <https://www.nexalistherapeutics.com>